• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Bone marrow histology from the clinical point of view].

作者信息

Seiler T, Dreyling M

机构信息

Medizinische Klinik und Poliklinik III, Klinikum der Universität München Großhadern, Marchioninistr 15, 81377 München, Deutschland.

出版信息

Pathologe. 2012 Nov;33(6):490-5. doi: 10.1007/s00292-012-1648-y.

DOI:10.1007/s00292-012-1648-y
PMID:23085693
Abstract

Bone marrow diagnostics is an essential tool in routine hematological clinical practice. Not only conventional cytological and histological approaches but also more modern techniques, such as immunohistochemistry, cytogenetics and molecular diagnostics are used. The molecular basis of more and more hematological disorders is being discovered and makes its way not only into routine diagnostics but also into daily clinical practice. Recurrent genomic aberrations associated with the individual patient prognosis are well characterized and are being applied in differential therapeutic decisions. In addition, understanding deregulated biochemical pathways have led to the development of targeted therapeutic approaches. This review outlines the value of bone marrow diagnostics in hematological diseases with a focus on the currently emerging molecular diagnostic possibilities.

摘要

相似文献

1
[Bone marrow histology from the clinical point of view].
Pathologe. 2012 Nov;33(6):490-5. doi: 10.1007/s00292-012-1648-y.
2
[Normal bone marrow and common reactive alterations].[正常骨髓及常见反应性改变]
Pathologe. 2012 Nov;33(6):496-507. doi: 10.1007/s00292-012-1649-x.
3
[Bone marrow diagnostics: integrative evaluation of results is a duty].
Pathologe. 2012 Nov;33(6):479-80. doi: 10.1007/s00292-012-1646-0.
4
An appraisal of the value of the bone marrow biopsy in the assessment of proliferative lesions of the bone marrow.
Histopathology. 1983 Sep;7(5):627-44. doi: 10.1111/j.1365-2559.1983.tb02276.x.
5
[Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases].[临床血液学中的Jamshidi活检。1000余例完整活检的方法、适应证及结果,特别提及慢性骨髓增殖性疾病]
Wien Med Wochenschr Suppl. 1986;100:1-24.
6
A study of the value of closed bone marrow biopsy.闭合性骨髓活检的价值研究
S Afr Med J. 1976 Nov 13;50(48):1928-31.
7
[Cytogenetic studies in the hematologic neoplasias].[血液系统肿瘤的细胞遗传学研究]
Sangre (Barc). 1995 Dec;40(6):521.
8
[Bone marrow biopsy: processing and use of molecular techniques].[骨髓活检:分子技术的处理与应用]
Pathologe. 2012 Nov;33(6):481-9. doi: 10.1007/s00292-012-1647-z.
9
[Lymphomas and lymphatic leukemias in the bone marrow].[骨髓中的淋巴瘤和淋巴性白血病]
Pathologe. 2012 Nov;33(6):518-27. doi: 10.1007/s00292-012-1652-2.
10
Clonality in context: hematopoietic clones in their marrow environment.背景下的克隆性:骨髓环境中的造血克隆
Blood. 2017 Nov 30;130(22):2363-2372. doi: 10.1182/blood-2017-07-794362. Epub 2017 Oct 18.

本文引用的文献

1
Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.重新探讨 5q 髓系恶性肿瘤的解剖学、临床和基因组相关性。
J Clin Oncol. 2012 Apr 20;30(12):1343-9. doi: 10.1200/JCO.2011.36.1824. Epub 2012 Feb 27.
2
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).英国骨髓瘤论坛(UKMF)和北欧骨髓瘤研究小组(NMSG):新检测到的M蛋白的调查及意义未明的单克隆丙种球蛋白病(MGUS)管理指南。
Br J Haematol. 2009 Oct;147(1):22-42. doi: 10.1111/j.1365-2141.2009.07807.x. Epub 2009 Aug 10.
3
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
世界卫生组织(WHO)髓系肿瘤和急性白血病分类的2008年修订版:基本原理及重要变化
Blood. 2009 Jul 30;114(5):937-51. doi: 10.1182/blood-2009-03-209262. Epub 2009 Apr 8.
4
Genetic complexity of myeloproliferative neoplasms.骨髓增殖性肿瘤的遗传复杂性
Leukemia. 2008 Oct;22(10):1841-8. doi: 10.1038/leu.2008.233. Epub 2008 Aug 28.
5
JAK and MPL mutations in myeloid malignancies.髓系恶性肿瘤中的JAK和MPL突变
Leuk Lymphoma. 2008 Mar;49(3):388-97. doi: 10.1080/10428190801895360.
6
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.慢性淋巴细胞白血病诊断与治疗指南:慢性淋巴细胞白血病国际研讨会报告,更新美国国立癌症研究所工作组1996年指南
Blood. 2008 Jun 15;111(12):5446-56. doi: 10.1182/blood-2007-06-093906. Epub 2008 Jan 23.
7
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.真性红细胞增多症和特发性红细胞增多症中的JAK2外显子12突变
N Engl J Med. 2007 Feb 1;356(5):459-68. doi: 10.1056/NEJMoa065202.
8
Revised response criteria for malignant lymphoma.恶性淋巴瘤修订后的反应标准。
J Clin Oncol. 2007 Feb 10;25(5):579-86. doi: 10.1200/JCO.2006.09.2403. Epub 2007 Jan 22.
9
Philadelphia positive acute lymphoblastic leukaemia of childhood.儿童费城染色体阳性急性淋巴细胞白血病
Br J Haematol. 2005 Aug;130(4):489-500. doi: 10.1111/j.1365-2141.2005.05611.x.
10
Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.Campath-1H诱导慢性淋巴细胞白血病完全缓解,尽管存在p53基因突变且对化疗耐药。
N Engl J Med. 2002 Aug 8;347(6):452-3. doi: 10.1056/NEJM200208083470619.